PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST‐IN‐CLASS ANTI‐CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO‐001, IN ADVANCED B‐CELL MALIGNANCIES. (12th June 2019)